Purpose: Current HIRA’s guideline recommends that economic evaluation (EE) analysis should take societal perspective, yet the inconsistency in current guideline has been noted by the industry side. The purpose of this study is to review current theoretical trends and discuss the needs of updating HIRA’s current recommendations. Methods: To identify the needs of EE guideline revision, HIRA has reviewed currently updated foreign EE guidelines, and discussed recent theoretical trends. In addition, survey results from pharmaceutical companies as well as decision makers regarding current recommendation were considered. Experts meetings and working group meetings with industry people were held to share each party’s perspectives.      Results: Pharmaceutical industry suggested that current recommendation of taking societal perspective while submitting indirect cost (especially productivity cost) separately is confusing. Canada (CADTH) has recently updated its perspective as “publicly funded health care system”, and UK (NICE) has recommended to take payer(NHS and PSS)’s perspective. Inconsistencies in societal perspective have also discussed in previous studies and ISPOR consensus paper.    Conclusions: Given that EE guideline should provide clear minimum standards for submission parties, a need to clarify current “societal” perspective has been agreed by relevant parties. “Limited” societal perspective has been proposed to reduce unnecessary confusions while reflecting current practice patterns.